SimBioSys announced that it received its second FDA 510(k) clearance for TumorSight Viz to expand its use by breast surgeons in the U.S.

Medtronic and Recor Medical each announced separate Medicare reimbursement approvals for their respective renal denervation (RDN) technologies.